LONDON, July 2 (Reuters) – Prime Minister David Cameron
called on Wednesday for global action to tackle the threat of
drug-resistant superbugs and said Britain planned to take a
leading role in finding ways to spur the development of new
A world without effective antibiotics would push medicine
back into the “dark ages”, he said, with routine surgery,
treatments for cancer and organ transplants potentially becoming
LONDON (Reuters) – European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015.
The new drug, known as Abasria, is made by U.S. rival Eli Lilly, which has developed it as a so-called biosimilar version of Sanofi’s $8 billion-a-year Lantus, or insulin glargine.
LONDON, June 26 (Reuters) – A vote by U.S. experts against
accelerated approval of a new ovarian cancer drug from
AstraZeneca has dented its claims of research prowess,
which were used to see off a $118 billion bid from Pfizer
In itself, the setback will have little impact on earnings
prospects – but it coincides with heightened scrutiny of the
British drugmaker’s research and development (R&D) machine and
continued talk that Pfizer may return if it stumbles.
LONDON (Reuters) – U.S. drugmaker AbbVie set out the strategic rationale for acquiring Shire on Wednesday as a battle for control of the London-listed company, which has spurned AbbVie’s $46 billion bid, entered a new phase.
AbbVie called for talks and said it was willing to move quickly and cooperatively to clinch a deal, arguing it would create more value from Shire’s assets than the hyperactivity and rare diseases specialist could do on its own.